Hims & Hers Stock Surges 48% In One Week Thanks to RFK Jr.’s Peptide Push
Topline
Hims & Hers Health inventory climbed as a lot as 11% Monday, persevering with a week-long rally after the FDA introduced a gathering to talk about easing peptide regulation—a push repeatedly championed by Robert F. Kennedy Jr.
(Photo by Alex Wong/Getty Images)
Getty Images
Key Facts
Hims & Hers inventory is up as a lot as 11% at the moment and has emerged greater than 125% since its lows in February, when the inventory was experiencing a chronic downturn that began late 2025.
Last week, the inventory started rallying after the FDA introduced it might maintain a gathering in July to think about easing regulation round peptides—the overarching class of medicine that not solely embrace the well-known and controlled GLP-1s, but additionally varied gray-market injectables which have exploded in reputation on social media on guarantees of outcomes like higher pores and skin, sooner therapeutic and slower growing old.
On April 15, Health Secretary Robert F. Kennedy Jr. introduced the FDA—which restricted 19 peptides in 2023 citing well being dangers—will consider eradicating 12 peptides from its restrictions, doubtlessly clearing a regulatory path for telehealth platforms together with Hims to supply peptide therapies.
RFK Jr. has lengthy been a loud proponent of peptides, claiming on Joe Rogan’s podcast in February that he has personally benefited from utilizing peptides.
Hims acquired a California-based peptide manufacturing facility in February 2025, positioning the corporate to produce peptide therapies at scale ought to regulate green-light the class.
Key Background
Hims & Hers constructed its enterprise on direct-to-consumer prescriptions for well being circumstances together with hair loss, erectile dysfunction, psychological well being and skincare, however its breakout progress got here from promoting compounded variations of GLP-1 weight-loss medicine through the shortages of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound round 2024. That technique fueled a 59% income enhance in 2025 to $2.35 billion however uncovered the corporate to important regulatory and authorized threat. An preliminary April 2025 partnership between Hims and Novo Nordisk collapsed inside two months after Novo accused the telehealth firm of “deceptive promotion” of “knockoff” Wegovy variations—setting off almost a yr of litigation, FDA warning letters and public feuding. In March, Hims and Novo Nordisk entered an settlement for Hims to prioritize distributing Novo’s branded GLP-1s in trade for Novo to drop the lawsuit. With Hims’ extremely worthwhile GLP-1 product changed with branded variations—and administration guiding softer 19% income progress this yr—the corporate is pivoting to new avenues to herald comparable revenue margins as the burden loss drug. The firm confirmed in its February earnings name that it’s creating a peptide-based product line as a part of a long life specialty deliberate to launch this yr.
Big Number
$500 billion. That’s how a lot market cap Novo Nordisk has misplaced from its peak in 2024. Once Europe’s most dear firm, the GLP-1 maker has confronted growing competitors from American competitor Eli Lilly and compounding pharmacies like Hims that pressured it to lower costs dramatically to keep market share.
Tangent
Peptides have turn out to be one of many buzziest wellness traits on the web at the moment. Compounds like BPC-157, GHK-Cu and varied GLP analogs have proliferated longevity throughout clinics, influencer advertising and marketing channels and gray-market retailers over the previous three years, often offered with claims about tissue restore, fats loss, pores and skin well being and “organic age reversal.” Much of that market operated in a regulatory limbo—not fairly prescription drug, not fairly complement—till the FDA’s 2023 restrictions formalized which peptides might and could not be produced by compounding pharmacies like Hims. The restrictions have led to the surging reputation of peptides imported from abroad, with “Chinese peptides” changing into a biohacking fad amongst Silicon Valley’s younger tech staff, in accordance to the New York Times. These unregulated compounds have additionally been reaching more and more younger audiences as “looksmaxxers”—younger males on social media who interact in excessive measures to maximize their bodily look—have notoriously used and promoted them.
